4.3 Article

New glycemic targets for patients with diabetes from the Japan Diabetes Society

期刊

JOURNAL OF DIABETES INVESTIGATION
卷 8, 期 1, 页码 123-125

出版社

WILEY
DOI: 10.1111/jdi.12600

关键词

Diabetes mellitus; HbA1c; Kumamoto Declaration 2013

资金

  1. Astellas Pharma Inc.
  2. Takeda Pharmaceutical Company Limited.
  3. Mitsubishi Tanabe Pharma Corporation
  4. Daiichi Sankyo Company, Limited
  5. Taisho Pharmaceutical Holdings Co., Ltd.
  6. Ono Pharmaceutical Co., LTD.
  7. MSD
  8. Grants-in-Aid for Scientific Research [26000012, 15K09394, 15K15348] Funding Source: KAKEN

向作者/读者索取更多资源

In the 'Evidence-based Practice Guideline for the Treatment for Diabetes in Japan 2013', a new concept of the glycemic control in patients with diabetes in Japan has been declared from the Japan Diabetes Society. The main objective value of HbA1c was set to <7% from the perspective of preventing microvascular complications. On the other hand, the objective in cases where objectives can be attained by appropriate dietary or exercise therapy, or during pharmacotherapy without the occurrence of side effects such as hypoglycemia was set to <6%, and the objective in cases where intensification of treatment was considered difficult due to side effects such as hypoglycemia or for other reasons was set to <8%. Treatment objectives should be established individually, in consideration of age, duration of disease, organ damage, risk of hypoglycemia, support structure, and etc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据